Nebius Accelerates Next Generation of Healthcare and Life Sciences Innovation with Inaugural AI Discovery Awards

• Full-stack AI infrastructure provider backs pioneering companies in biotech, drug discovery, genomics and multiomics, and healthcare diagnostics with GPU cloud and inferencing credits totalling over $850,000.

Amsterdam, Netherlands--(Newsfile Corp. - June 23, 2025) - Nebius (NASDAQ: NBIS) has named the winners of its inaugural AI Discovery Awards, awarding top prizes of $100,000 in GPU credits each to four companies pioneering AI breakthroughs in cancer prediction, protein targeting, transcriptomic mapping, and precision diagnostics.

The winners, selected from 257 global applications by a panel of 19 independent judges from leading biotech, pharma, research and venture capital organizations, represent validated AI solutions with clear paths to market impact:

Biotechnology: Ataraxis AI - Cancer treatment prediction platform achieved 30% higher accuracy than standard genomic tests in clinical validation across 7,500 patients from 15 institutions. The Kestrel foundation model, trained on hundreds of millions of pathology images, helps oncologists determine whether aggressive treatments like chemotherapy are necessary.

Drug Discovery: Aikium - Targets "undruggable" proteins comprising half the human proteome using its Yotta-ML² platform. The company has secured partnerships with four organizations, including three top cancer hospitals, based on successful GPCR proof-of-concept work.

Genomics and Multiomics: Transcripta Bio - Built a high-resolution transcriptomic atlas containing over a billion gene responses to power AI models predicting biological responses from drug molecules. Recently partnered with Microsoft Research to identify new disease-gene associations.

HealthTech: MetaSight Diagnostics - Pioneers population-scale disease diagnostics through advanced blood testing, creating the world's largest blood molecular database from over 500,000 participants in the Israel Multi-OMICS Screening Trial. Developing screening products for colorectal cancer and metabolic diseases.

"These teams are pushing the frontier of AI in healthcare and life sciences with credible science and clear paths to market," said Arkady Volozh, founder and CEO of Nebius. "We're proud to help them turn research into real-world impact."

Held for the first time this year, the Nebius AI Discovery Awards connect promising companies leveraging AI in healthcare and life sciences with the computational infrastructure and expertise needed to scale their innovations.